LONDON (dpa-AFX) - Overall survival results from the TROPION-Lung01 phase 3
trial numerically favored Daiichi Sankyo and AstraZeneca's datopotamab
deruxtecan (Dato-DXd) compared to docetaxel in the overall trial population of
adult patients with locally advanced or metastatic non-small cell lung cancer or
NSCLC treated with at least one prior line of therapy. But survival results did
not reach statistical significance in the overall trial population, AstraZeneca
said in a statement.

The TROPION-Lung01 phase 3 trial previously met the dual primary endpoint of
progression-free survival (PFS).

In the pre-specified subgroup of patients with nonsquamous NSCLC, datopotamab
deruxtecan showed a clinically meaningful improvement in Overall survival
compared to docetaxel, the current standard of care chemotherapy.

The safety profile of datopotamab deruxtecan in TROPION-Lung01 was consistent
with the previous analysis, including fewer dose reductions or discontinuations
due to adverse events compared to docetaxel and with no new safety concerns
identified. No new interstitial lung disease events of any grade were
adjudicated as drug-related.

Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody
drug conjugate discovered by Daiichi Sankyo and being jointly developed by
Daiichi Sankyo and AstraZeneca.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX